Patient characteristics of those with MM
| Characteristics . | Overall . |
|---|---|
| N = 6062 . | |
| Demographics | |
| Age at MM diagnosis, y | |
| Mean ± SD | 65.0 ± 11.6 |
| Median (IQR) | 65.0 (58.0-73.0) |
| Age range, n (%) | |
| 18-44 | 263 (4.3) |
| 45-64 | 2558 (42.2) |
| ≥65 | 3241 (53.5) |
| Sex, n (%) | |
| Male | 3409 (56.2) |
| Female | 2653 (43.8) |
| Race, n (%) | |
| White | 5164 (85.2) |
| Black or African American | 380 (6.3) |
| Asian | 132 (2.2) |
| American Indian or Alaska Native | 9 (0.1) |
| Native Hawaiian and other Pacific Islander | 3 (0.0) |
| Multiracial | 46 (0.8) |
| Other | 159 (2.6) |
| Unknown | 169 (2.8) |
| Clinical characteristics | |
| BMI,∗ kg/m2 | |
| Mean ± SD | 28.2 ± 5.8 |
| Median (IQR) | 27.4 (24.2-31.1) |
| Unknown | 1133 (18.7) |
| Disease characteristics | |
| Year of MM diagnosis, n (%) | |
| 2010-2015 | 1878 (31.0) |
| 2016-2023 | 4184 (69.0) |
| Follow-up period from MM diagnosis to end of follow-up, y | |
| Mean ± SD | 5.0 ± 3.2 |
| Median (IQR) | 4.6 (2.4-7.2) |
| Treatment characteristics,† n (%) | |
| Proteasome inhibitors‡ | 3011 (49.7) |
| Immunotherapy§ | 2599 (42.9) |
| Immunomodulatory agents|| | 2459 (40.6) |
| Alkylating agents¶ | 2214 (36.5) |
| HSCT | 2109 (34.8) |
| CAR T-cell therapy | 340 (5.6) |
| BsAbs# | 67 (1.1) |
| Characteristics . | Overall . |
|---|---|
| N = 6062 . | |
| Demographics | |
| Age at MM diagnosis, y | |
| Mean ± SD | 65.0 ± 11.6 |
| Median (IQR) | 65.0 (58.0-73.0) |
| Age range, n (%) | |
| 18-44 | 263 (4.3) |
| 45-64 | 2558 (42.2) |
| ≥65 | 3241 (53.5) |
| Sex, n (%) | |
| Male | 3409 (56.2) |
| Female | 2653 (43.8) |
| Race, n (%) | |
| White | 5164 (85.2) |
| Black or African American | 380 (6.3) |
| Asian | 132 (2.2) |
| American Indian or Alaska Native | 9 (0.1) |
| Native Hawaiian and other Pacific Islander | 3 (0.0) |
| Multiracial | 46 (0.8) |
| Other | 159 (2.6) |
| Unknown | 169 (2.8) |
| Clinical characteristics | |
| BMI,∗ kg/m2 | |
| Mean ± SD | 28.2 ± 5.8 |
| Median (IQR) | 27.4 (24.2-31.1) |
| Unknown | 1133 (18.7) |
| Disease characteristics | |
| Year of MM diagnosis, n (%) | |
| 2010-2015 | 1878 (31.0) |
| 2016-2023 | 4184 (69.0) |
| Follow-up period from MM diagnosis to end of follow-up, y | |
| Mean ± SD | 5.0 ± 3.2 |
| Median (IQR) | 4.6 (2.4-7.2) |
| Treatment characteristics,† n (%) | |
| Proteasome inhibitors‡ | 3011 (49.7) |
| Immunotherapy§ | 2599 (42.9) |
| Immunomodulatory agents|| | 2459 (40.6) |
| Alkylating agents¶ | 2214 (36.5) |
| HSCT | 2109 (34.8) |
| CAR T-cell therapy | 340 (5.6) |
| BsAbs# | 67 (1.1) |
BMI, body mass index; HSCT, hematopoietic stem cell transplantation.
The BMI value measured closest to the date of MM diagnosis is reported.
Identified using structured and unstructured data from the MGB database.
Proteasome inhibitors include bortezomib, carfilzomib, and ixazomib.
Immunotherapy includes daratumumab, elotuzumab, and isatuximab.
Immunomodulatory agents include lenalidomide, pomalidomide, and thalidomide.
Alkylating agents include melphalan, bendamustine, doxorubicin, cisplatin, and cyclophosphamide.
BsAbs include teclistamab, blinatumomab, and emicizumab.